Completed PHASE2 NCT00091832

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.

Sponsor: Amgen

Conditions Bone Metastases in Subjects With Advanced Breast Cancer Breast Cancer Metastases

Interventions Denosumab IV Bisphosphonates

Updated 5 times since 2017 Last updated: Dec 20, 2013 Started: Sep 30, 2004 Primary completion: Nov 30, 2005 Completion: Oct 31, 2006

Listed as NCT00091832, this PHASE2 trial focuses on Bone Metastases in Subjects With Advanced Breast Cancer and Breast Cancer and remains completed. Sponsored by Amgen, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.